VA
NVAX icon

VR Adviser’s Novavax NVAX Stock Holding History

VR Adviser’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,879,894
Closed -$19.3M – 28
2022
Q4 		$19.3M Buy
+1,879,894
New +$33.2M 3.26% 12

Other funds holding NVAX

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Shah Capital Management Raleigh, North Carolina $526M AUM 46.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Coatue Management
Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

VR Adviser's NVAX Position: Q1 2023 in Review

VR Adviser sold out of Novavax (NVAX) in Q1 2023, closing a stake of 1,879,894 shares — an estimated $19.3M sold.

VR Adviser first reported a position in NVAX in Q4 2022 and held it in 1 quarter. The position peaked at $19.3M in Q4 2022. 222 funds tracked by Wall St. Rank hold NVAX as of Q1 2023.

  • VR Adviser reported no remaining Novavax position as of Q1 2023 after selling out during the quarter.
  • VR Adviser sold 1,879,894 Novavax shares in Q1 2023, an estimated $19.3M.
  • VR Adviser first reported a position in Novavax in Q4 2022 and held it in 1 quarter.
  • VR Adviser's Novavax position peaked at $19.3M in Q4 2022.
  • 222 funds tracked by Wall St. Rank held Novavax as of Q1 2023.

Based on VR Adviser's 13F filing for Q1 2023, filed 15 May 2023.